TCR2 Therapeutics Inc expected to post a loss of 79 cents a share - Earnings Preview

TCR2 Therapeutics

17/03/2023 11:16

* TCR2 Therapeutics Inc  TCRR.OQ   TCRR.O  is expected
to show no
change in quarterly revenue when it reports  results on March 20
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for TCR2 Therapeutics
Inc is
for a loss of 79 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 6
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for TCR2
Therapeutics
Inc is $3​, above​ its last closing price of $1.56. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.84       -0.83      -0.79     Beat    5.4
 Jun. 30 2022  -0.79       -0.79      -0.82     Missed  -3.8
 Mar. 31 2022  -0.74       -0.74      -0.76     Missed  -2.1​
 Dec. 31 2021  -0.74       -0.75      -0.72     Beat    3.9
 ​​Sep.        -0.69       -0.65      -0.69     Missed  -6.3
 30 2021                                                
 Jun. 30 2021  -0.61       -0.59      -0.64     Missed  -8.8​
 Mar. 31 2021  -0.53       -0.53      -0.58     Missed  -10.4
 Dec. 31 2020  -0.52       -0.56      -0.55     Beat    2
 This summary was machine generated March 17 at 11:16 GMT.  All
figures in US dollars  unless otherwise stated